Calliditas Therapeutics AB (publ) (CALT) News Today → 4 Cryptos BETTER than Bitcoin (From True Market Insiders) (Ad) Free CALT Stock Alerts $37.95 +15.53 (+69.27%) (As of 05/28/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 29 at 2:36 AM | americanbankingnews.comCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Receives "Hold" Rating from Stifel NicolausMay 28 at 10:53 PM | finance.yahoo.comSwedish Exchange Growth Leaders: 3 Companies With Significant Insider OwnershipMay 28 at 5:53 PM | markets.businessinsider.comMaintaining Hold on Calliditas: Assessing Acquisition Fairness Amid Evolving IgAN Market DynamicsMay 28 at 5:26 PM | marketbeat.comJefferies Financial Group Reiterates Hold Rating for Calliditas Therapeutics AB (publ) (NASDAQ:CALT)Jefferies Financial Group reissued a "hold" rating and set a $39.00 target price (down from $58.00) on shares of Calliditas Therapeutics AB (publ) in a report on Tuesday.May 28 at 12:52 PM | benzinga.comDow Dips Over 100 Points; GameStop Shares Spike higherMay 28 at 12:52 PM | benzinga.comAsahi Kasei Makes $1.1B Offer For Swedish Drugmaker Calliditas Therapeutics, Enhancing Pharma Growth StrategyMay 28 at 12:52 PM | seekingalpha.comAsahi Kasei To Pay A Fair Price For Calliditas TherapeuticsMay 28 at 10:42 AM | americanbankingnews.comCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Reaches New 52-Week High at $38.32May 28 at 8:36 AM | prnewswire.comCalliditas Therapeutics Presents Data at the 61st European Renal Association CongressMay 28 at 8:20 AM | businesswire.comCALT STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of Calliditas Therapeutics AB Is Fair to ShareholdersMay 28 at 7:51 AM | finance.yahoo.comAsahi Kasei Makes $1.1 Billion Bid For Swedish Calliditas TherapeuticsMay 28 at 3:16 AM | reuters.comAsahi Kasei to buy Swedish drugmaker Calliditas for $1.1 billionMay 28 at 3:14 AM | prnewswire.comStatement by the Board of Directors of Calliditas Therapeutics AB (publ) in relation to the public offer by Asahi Kasei CorporationMay 26 at 2:52 AM | americanbankingnews.comCalliditas Therapeutics AB (publ) (NASDAQ:CALT) PT Lowered to $45.00 at HC WainwrightMay 25, 2024 | americanbankingnews.comCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Announces Quarterly Earnings Results, Misses Expectations By $0.74 EPSMay 25, 2024 | americanbankingnews.comCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Trading Down 3.1% Following Weak EarningsMay 24, 2024 | markets.businessinsider.comBuy Rating Affirmed for Calliditas Therapeutics Amid Strong Growth and Expanding Market OpportunitiesMay 24, 2024 | marketbeat.comCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Shares Down 3.1% Following Weak EarningsCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Stock Price Down 3.1% After Earnings MissMay 24, 2024 | msn.comCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Q1 2024 Earnings Call TranscriptMay 24, 2024 | marketbeat.comCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Issues Quarterly Earnings ResultsCalliditas Therapeutics AB (publ) (NASDAQ:CALT - Get Free Report) announced its quarterly earnings data on Thursday. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.74). Calliditas Therapeutics AB (publ) had a negative return on equity of 104.47% and a negative net margin of 38.72%.May 24, 2024 | marketbeat.comCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Price Target Cut to $45.00HC Wainwright dropped their price target on Calliditas Therapeutics AB (publ) from $50.00 to $45.00 and set a "buy" rating for the company in a research note on Friday.May 23, 2024 | marketbeat.comCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Shares Gap Up to $21.71Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Shares Gap Up to $21.71May 23, 2024 | seekingalpha.comCalliditas Therapeutics AB (publ) 2024 Q1 - Results - Earnings Call PresentationMay 23, 2024 | finance.yahoo.comCalliditas Q1 report, January - March 2024May 23, 2024 | prnewswire.comCalliditas Q1 report, January - March 2024May 22, 2024 | markets.businessinsider.comHere's what Wall Street expects from Calliditas Therapeutics (spons ADRs)'s earnings reportMay 18, 2024 | finanznachrichten.deCalliditas Therapeutics: In-Person & Virtual R&D Day: The Anti-Fibrotic Effects of Setanaxib and TARPEYO's Mode of ActionMay 16, 2024 | prnewswire.comIn-Person & Virtual R&D Day: The Anti-Fibrotic Effects of Setanaxib and TARPEYO's Mode of ActionMay 16, 2024 | finance.yahoo.comInvitation to the presentation of Calliditas´s interim report January - March 2024May 15, 2024 | prnewswire.comCalliditas Therapeutics to Present Data at ERA 2024 May 23 - 26 in StockholmMay 15, 2024 | prnewswire.comNotice of annual general meeting of Calliditas Therapeutics AB (publ)May 14, 2024 | finance.yahoo.comExploring Three Swedish Growth Companies With High Insider Ownership On The Swedish ExchangeMay 14, 2024 | marketbeat.comCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Shares Gap Up to $21.02Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Shares Gap Up to $21.02May 14, 2024 | prnewswire.comCalliditas' Partner Everest Medicines Starts Commercial Launch of Nefecon in ChinaMay 6, 2024 | markets.businessinsider.comWhat Wall Street expects from Calliditas Therapeutics (spons ADRs)'s earningsMay 6, 2024 | msn.comCalliditas releases phase 2 results on head and neck cancer asset setanaxibMay 6, 2024 | prnewswire.comCalliditas announces positive topline results of Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxibApril 30, 2024 | marketbeat.comCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Shares Gap Up to $18.65Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Shares Gap Up to $18.65April 29, 2024 | marketbeat.comCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Stock Price Down 9.3%Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Stock Price Down 9.3%April 26, 2024 | marketbeat.comCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Short Interest Up 121.9% in AprilCalliditas Therapeutics AB (publ) (NASDAQ:CALT - Get Free Report) saw a large increase in short interest during the month of April. As of April 15th, there was short interest totalling 7,100 shares, an increase of 121.9% from the March 31st total of 3,200 shares. Based on an average trading volume of 7,300 shares, the days-to-cover ratio is presently 1.0 days.April 24, 2024 | finance.yahoo.comCalliditas Therapeutics' 2023 Annual Report PublishedApril 24, 2024 | prnewswire.comCalliditas Announces Positive NefIgArd Open Label Extension ResultsApril 22, 2024 | marketbeat.comCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Trading Down 6.4%Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Trading Down 6.4%April 19, 2024 | marketbeat.comCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Trading 3.4% Higher Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Stock Price Up 3.4%April 19, 2024 | benzinga.comLatest News for Calliditas Therapeutics Stock (NASDAQ:CALT)April 18, 2024 | marketbeat.comCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Shares Gap Down to $18.74Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Shares Gap Down to $18.74April 18, 2024 | prnewswire.comCalliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024April 11, 2024 | markets.businessinsider.comBuy Rating Affirmed for Calliditas Therapeutics Amid Positive Market Trends and Upcoming CatalystsApril 11, 2024 | marketbeat.comCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Short Interest Down 56.2% in MarchCalliditas Therapeutics AB (publ) (NASDAQ:CALT - Get Free Report) saw a significant drop in short interest in March. As of March 31st, there was short interest totalling 3,200 shares, a drop of 56.2% from the March 15th total of 7,300 shares. Based on an average daily trading volume, of 7,900 shares, the days-to-cover ratio is presently 0.4 days.April 10, 2024 | marketbeat.comCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Stock Price Down 8.3%Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Trading Down 8.3% Get Calliditas Therapeutics AB (publ) News Delivered to You Automatically Sign up to receive the latest news and ratings for CALT and its competitors with MarketBeat's FREE daily newsletter. Email Address 4 Cryptos BETTER than Bitcoin (Ad)Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than Bitcoin Click For My #1 FREE Crypto for 2024 CALT Media Mentions By Week CALT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CALT News Sentiment▼0.010.82▲Average Medical News Sentiment CALT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CALT Articles This Week▼342▲CALT Articles Average Week Get Calliditas Therapeutics AB (publ) News Delivered to You Automatically Sign up to receive the latest news and ratings for CALT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Mineralys Therapeutics News GH Research News Zymeworks News Phathom Pharmaceuticals News AnaptysBio News Pharvaris News Lyell Immunopharma News ArriVent BioPharma News Pharming Group News Arbutus Biopharma News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CALT) was last updated on 5/29/2024 by MarketBeat.com Staff From Our Partners4 Cryptos BETTER than BitcoinTrue Market InsidersHe Is Giving Away BitcoinCrypto Swap ProfitsA once-in-a-century investment opportunityStansberry ResearchThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaWrite this ticker symbol down…StocksToTradeMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemWeiss RatingsTop 5 AI Stocks to Buy for 2024Market Moving Trends Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Calliditas Therapeutics AB (publ) Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
